Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD

NCT04957823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-02-29

No results posted yet for this study

Summary

This is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism and the presence and severity of coronary artery disease in patients with Type II DM.

Conditions

  • Irisin Gene Polymorphism in Type II Diabetic Patients

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-20
Primary Completion
2022-08-30
Completion
2023-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04957823 on ClinicalTrials.gov